inflammatory bowel disease

News

MSD taps Quotient for IBD drug targets in $2.2bn deal

MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.

News

MSD and Mayo Clinic team up on AI drug discovery

MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.

News

Boehringer signs €1bn+ deal for Simcere IBD candidate

Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.

News

A person putting wooden puzzle pieces together above grass

Abivax climbs on Lilly takeover speculation

Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.

News

OMass attracts $420m Roche wager on IBD programme

UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.

News

Vedanta's microbiome therapy for IBD disappoints

Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.

MSD taps Quotient for IBD drug targets in $2.2bn deal

MSD and Mayo Clinic team up on AI drug discovery

Boehringer signs €1bn+ deal for Simcere IBD candidate

Abivax climbs on Lilly takeover speculation

OMass attracts $420m Roche wager on IBD programme

Vedanta's microbiome therapy for IBD disappoints

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

inflammatory bowel disease

Editor's Picks